Charles River Laboratories International Quarterly Balance Sheet
NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 12, 4:00 PM ET · Delayed 15 min
Charles River Laboratories International financial position
As of Jun 27, 2026, Charles River Laboratories International reported total assets of $7.53 billion, down 0.4% from a year earlier against total liabilities of $4.64 billion. Shareholders' equity stood at $2.84 billion, or 37.7% of assets. The company held $192.0 million in cash and equivalents against $2.63 billion of debt, a net debt position of $2.43 billion.
The current ratio (current assets divided by current liabilities) was 1.35, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.92.
Summary generated from market data by MetaCap's automated system. Methodology
Charles River Laboratories International balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-27 | Q1 20262026-03-28 | Q4 20252025-12-27 | Q3 20252025-09-27 | Q2 20252025-06-28 | Q1 20252025-03-29 | Q4 20242024-12-28 | Q3 20242024-09-28 | Q2 20242024-06-29 | Q1 20242024-03-30 | Q4 20232023-12-30 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 192.03M | 191.83M | 213.77M | 207.10M | 182.82M | 229.36M | 194.61M | 210.17M | 179.21M | 327.04M | 276.77M | 157.17M |
| Receivables | 711.75M | 700.25M | 708.86M | 734.48M | 767.57M | 756.63M | 720.91M | 754.21M | 762.22M | 786.98M | 780.38M | 799.31M |
| Inventory | 346.26M | 359.72M | 299.10M | 302.55M | 279.55M | 290.16M | 278.54M | 336.20M | 349.11M | 361.28M | 380.26M | 292.97M |
| Total Current Assets | 1.53B | 1.49B | 1.45B | 1.53B | 1.47B | 1.51B | 1.40B | 1.49B | 1.50B | 1.67B | 1.61B | 1.44B |
| Property, Plant & Equipment | 1.49B | 1.51B | 1.66B | 1.59B | 1.61B | 1.59B | 1.60B | 1.64B | 1.61B | 1.62B | 1.64B | 1.53B |
| Goodwill | 3.08B | 3.04B | 2.76B | 2.92B | 2.94B | 2.87B | 2.85B | 3.12B | 3.08B | 3.07B | 3.10B | 2.88B |
| Intangible Assets | 253.17M | 248.99M | 340.00M | 571.09M | 602.45M | 655.71M | 723.40M | 778.46M | 800.13M | 827.64M | 864.05M | 886.29M |
| Total Assets | 7.53B | 7.73B | 7.14B | 7.51B | 7.56B | 7.58B | 7.53B | 8.00B | 7.95B | 8.15B | 8.20B | 7.61B |
| Accounts Payable | 140.98M | 133.95M | 148.80M | 169.62M | 145.80M | 149.33M | 140.34M | 135.96M | 133.10M | 129.68M | 168.94M | 136.34M |
| Short-Term Debt | 5.46M | 6.70M | 166.00K | 54.00K | 98.00K | 121.00K | 155.00K | 157.00K | 435.00K | 459.00K | 3.17M | 797.00K |
| Total Current Liabilities | 1.13B | 1.09B | 1.12B | 1.12B | 1.08B | 1.05B | 994.10M | 1.01B | 947.52M | 954.81M | 1.06B | 993.82M |
| Long-Term Debt | 2.62B | 2.66B | 2.14B | 2.19B | 2.33B | 2.51B | 2.24B | 2.33B | 2.41B | 2.66B | 2.65B | 2.51B |
| Total Liabilities | 4.64B | 4.74B | 3.92B | 4.06B | 4.16B | 4.34B | 4.02B | 4.18B | 4.18B | 4.45B | 4.54B | 4.26B |
| Shareholders' Equity | 2.84B | 2.94B | 3.16B | 3.41B | 3.35B | 3.19B | 3.46B | 3.78B | 3.72B | 3.64B | 3.60B | 3.31B |
| Retained Earnings | 1.37B | 1.37B | 1.39B | 1.94B | 1.89B | 1.84B | 1.81B | 2.12B | 2.05B | 1.96B | 1.89B | 1.72B |
| Total Debt | 2.63B | 2.67B | 2.14B | 2.19B | 2.33B | 2.51B | 2.24B | 2.33B | 2.41B | 2.66B | 2.65B | 2.52B |
| Net Cash (Debt) | -2.43B | -2.48B | -1.92B | -1.98B | -2.15B | -2.28B | -2.05B | -2.12B | -2.23B | -2.33B | -2.37B | -2.36B |
| Shares Outstanding | 47.73M | 48.17M | 49.22M | 49.22M | 49.21M | 49.12M | 51.14M | 51.13M | 51.61M | 51.51M | 51.34M | 51.30M |
This table shows 12 quarterly periods of Charles River Laboratories International's balance sheet, from Q2 2026 back to Q3 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CRL's reporting calendar. What is a balance sheet?